Biopharmaceutical Product Attributes and Biological Consequences Community

Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

Brief Description:

The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

This talk will discuss: 

• new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
• how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

We look forward to your participation in a lively discussion on this topic!

When: 26th March 2024, 12 PM – 1 PM US EST

Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Suman Luthra
Director
Merck
Boston MA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

Brief Description:

The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

This talk will discuss: 

• new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
• how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

We look forward to your participation in a lively discussion on this topic!

When: 26th March 2024, 12 PM – 1 PM US EST

Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Suman Luthra
Director
Merck
Boston MA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

The BPABC Leadership Team is excited for the OSD with Chris Calderon! We invite you again to join the discussion. If you alreday have any questions, you can add them to this post.

Thank you!

Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

Brief Description:

The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

This talk will discuss: 

• new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
• how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

We look forward to your participation in a lively discussion on this topic!

When: 26th March 2024, 12 PM – 1 PM US EST

Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Suman Luthra
Director
Merck
Boston MA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

Brief Description:

The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

This talk will discuss: 

• new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
• how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

We look forward to your participation in a lively discussion on this topic!

When: 26th March 2024, 12 PM – 1 PM US EST

Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Suman Luthra
Director
Merck
Boston MA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------

Hello Suman,

Do you have the recording of the session by Chris Calderon, PhD. If so would you be able to upload on the community page or somewhere accessible?

Thanks

Asif Ali, Ph.D.
Formulation and Process Development Scientist
Alexion AstraZeneca Rare Diseases

New Haven, CT
[email protected]
973-960-7632

------------------------------


Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.

Original Message:
Sent: 03-13-2024 08:41
From: Suman Luthra
Subject: Open Scientific Discussion (OSD) with Chris Calderon - Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics: Applications to Protein and Cell-Based Therapeutics

Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

Brief Description:

The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

This talk will discuss: 

• new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
• how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

We look forward to your participation in a lively discussion on this topic!

When: 26th March 2024, 12 PM – 1 PM US EST

Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Suman Luthra
Director
Merck
Boston MA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------